tldrdailynews.com logo

ImmunityBio's bladder cancer therapy rejected by FDA, stock plummets.

1 min read
Source: Endpoints News
ImmunityBio's bladder cancer therapy rejected by FDA, stock plummets.
Photo: Endpoints News
TL;DR

The FDA has rejected ImmunityBio's biologics license application for a specific bladder cancer, citing deficiencies related to an inspection of a third-party contract manufacturer. The rejection caused the biotech's shares to tumble about 50%. ImmunityBio's Anktiva, or N-803, will need a satisfactory resolution of the observations before a BLA approval.

Topics:businessbiotech#biologics-license-application#biotech#bladder-cancer#fda#immunitybio#rejection
Share this article
  1. FDA rejects bladder cancer therapy developed by Patrick Soon-Shiong's ImmunityBio  Endpoints News
  2. FDA declines to approve ImmunityBio's bladder cancer therapy, shares slump  Reuters
  3. FDA Rejects ImmunityBio's Bladder Cancer Therapy, Sends Stock Tumbling  BioSpace
  4. ImmunityBio gets FDA snub on cancer drug, shares crash  FiercePharma
  5. Why Is ImmunityBio (IBRX) Stock Down 54% Today?  InvestorPlace
  6. View Full Coverage on Google News

Want the full story? Read the original reporting

Read on Endpoints News